Replies to post #199547 on Biotech Values

[DewDiligence]

Analysts’ forward P/E ratios for EGRX are wild guesses at this point because they don’t know how well Bendeka will sell. Moreover, EGRX and TEVA have not disclosed the sales threshold that lifts EGRX's royalty to more than the 20% base rate—not have they disclosed how high the royalty can go if sales exceed the sales threshold.